<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Apalutamide" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Apalutamide</book-part-id>
      <title-group>
        <title>Apalutamide</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="AntiviralAgents" document-type="chapter">Antiviral Agents</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Apixaban" document-type="chapter">Apixaban</related-object>
    </book-part-meta>
    <body>
      <sec id="Apalutamide.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Apalutamide.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Apalutamide is a third generation, oral nonsteroidal antiandrogen used to treat nonmetastatic castration-resistant prostate cancer. Apalutamide is associated with a low rate of serum enzyme elevation during therapy but has not been linked to cases of clinically apparent liver injury with jaundice.</p>
        </sec>
        <sec id="Apalutamide.Background">
          <title>Background</title>
          <p>Apalutamide (a pa lut' a mide) is a small molecule androgen receptor antagonist which binds to the intracellular receptor and prevents its translocation to the nucleus and subsequent DNA binding, thereby blocking its activity. Therapy with apalutamide lowers residual testosterone levels after surgical castration in men with prostate cancer and has been shown to prolong metastasis free survival in men with castration-resistant prostate cancer with rising levels of prostate-associated antigen (PSA) without measurable metastatic disease. Apalutamide was approved for use in the United States in 2018 and current indications include metastatic, castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer. Apalutamide is available as tablets of 60 and 240 mg under brand name Erleada. The recommended initial dose is 240 mg daily with subsequent dose reduction for intolerance. It should be administered with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy to insure optimal androgen suppression. Common side effects include symptoms of androgen deficiency including fatigue, diarrhea, nausea, anorexia, weight loss, constipation, joint and muscle pain, hot flushes, headaches, dizziness, and edema. Rare, but potentially serious side effects associated with long term therapy include seizures, osteoporosis, falls, bone fractures, severe cutaneous adverse events, embryo-fetal toxicity, and cardiovascular events.</p>
        </sec>
        <sec id="Apalutamide.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In prelicensure controlled trials of apalutamide, serum aminotransferase elevations were uncommon and generally transient and mild, not requiring dose modification. Clinically apparent liver injury with jaundice attributable to apalutamide was not reported in the preregistration trials and is not mentioned as an adverse event in the product label. Since the approval and general clinical use of apalutamide, there have been no publications or descriptions of the clinical features of hepatotoxicity with jaundice associated with its use. The first and second generation androgen receptor blockers, flutamide, nilutamide, and bicalutamide, have all been linked to instances of hepatitis-like liver injury with jaundice that can be severe and even fatal. However, such cases have not been described with apalutamide and other third generation androgen receptor antagonists. Thus, clinically apparent liver injury due to apalutamide must be rare, if it occurs at all.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Apalutamide.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The possible cause of liver injury due to apalutamide therapy is unknown. While first and second generation antiandrogens have been implicated in causing liver injury, the more potent third general factors have not. Apalutamide is extensively metabolized in the liver predominantly by CYP 2C8 and 3A and is an inducer of CYP 3A4. While coadministration of apalutamide with substrates of CYP 3A4 and with modulators of CYP 2C8 and 3A4 may result in drug-drug interactions, the effects are relatively modest.</p>
        </sec>
        <sec id="Apalutamide.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The liver injury linked to apalutamide therapy has been generally mild, consisting of transient and asymptomatic elevations in serum aminotransferase levels and rarely requiring dose modification or discontinuation. Apalutamide has not been linked to cases of acute liver failure, chronic hepatitis or vanishing bile duct syndrome. There is no information on cross sensitivity to hepatic injury between apalutamide and other antiandrogens, such as flutamide, bicalutamide, or abiraterone.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntineoplasticAgents" document-type="chapter">Antineoplastic Agents</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Anti-androgens" document-type="chapter">Antiandrogens</related-object></p>
        </sec>
      </sec>
      <sec id="Apalutamide.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Apalutamide &#x02013; Erleada&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Antineoplastic Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Apalutamide">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Apalutamide.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Apalutamide.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Apalutamide.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Apalutamide.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Apalutamide.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Apalutamide.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Apalutamide.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Apalutamide</td>
                <td headers="hd_h_Apalutamide.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://162108672">956104-40-8</ext-link>
</td>
                <td headers="hd_h_Apalutamide.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H15-F4-N5-O2-S</td>
                <td headers="hd_h_Apalutamide.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="162108672" document-id-type="sid" document-type="summary" object-id="162108672" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Apalutamide.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 15 March 2023</p>
        <p>Abbreviations: LHRH, luteinizing hormone releasing hormone, PSA, prostate-specific antigen.</p>
        <ref-list id="Apalutamide.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Apalutamide.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 673-708.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity of cancer chemotherapeutic agents published in 1999 before the availability of apalutamide).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Apalutamide.REF.deleve.2013">
            <mixed-citation publication-type="book">DeLeve LD. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam, Elsevier, 2013, p. 541-68.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of cancer chemotherapeutic agents; apalutamide is not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Apalutamide.REF.isaacs.2018">
            <mixed-citation publication-type="book">Isaacs C, Wellstein A, Riegel AT. Hormones and related agents in the therapy of cancer. Natural products in cancer chemotherapy: hormones and related agents. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1237-48.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics discusses the androgen receptor antagonists flutamide, bicalutamide, nilutamide and enzalutamide, but not apalutamide).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Apalutamide.REF.fda">
            <mixed-citation publication-type="web"><person-group><collab>FDA</collab></person-group>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/">https://www.accessdata.fda.gov/scripts/cder/daf/</ext-link><annotation><p><italic toggle="yes">(FDA Drug Approvals website that has product labels [package inserts], letters of approval and full FDA scientific review of the new drug application for safety and efficacy; mentions that hepatic laboratory abnormalities were uncommon and the single instance of clinically apparent liver injury with jaundice appeared to be due to progressive hepatic metastases rather than apalutamide toxicity).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Apalutamide.REF.tran.2009.787">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Tran</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Ouk</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Clegg</surname><given-names>NJ</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Watson</surname><given-names>PA</given-names></name>
<name name-style="western"><surname>Arora</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Wongvipat</surname><given-names>J</given-names></name>
<etal/>
</person-group>
              <article-title>Development of a second-generation antiandrogen for treatment of advanced prostate cancer.</article-title>
              <source>Science</source>
              <year>2009</year>
              <volume>324</volume>
              <fpage>787</fpage>
              <lpage>90</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Description of development of unique antiandrogen molecules that block the translocation of the androgen receptor to the nucleus and the transcriptional activity of the receptor).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">19359544</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.smith.2016.963">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Smith</surname><given-names>MR</given-names></name>
<name name-style="western"><surname>Antonarakis</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Ryan</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Berry</surname><given-names>WR</given-names></name>
<name name-style="western"><surname>Shore</surname><given-names>ND</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Alumkal</surname><given-names>JJ</given-names></name>
<etal/>
</person-group>
              <article-title>Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort.</article-title>
              <source>Eur Urol</source>
              <year>2016</year>
              <volume>70</volume>
              <fpage>963</fpage>
              <lpage>70</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 51 patients with castration-resistant prostate cancer and rising levels of PSA who were treated with apalutamide [240 mg daily], 89% had a 50% decline in PSA levels within 12 weeks and common side effects were fatigue [61%], diarrhea [43%], nausea [39%], joint and back pain [22%], hot flush [20%] and abdominal pain [18%], and no serious adverse events occurred; no mention of ALT elevations or hepatotoxicity).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">27160947</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.rathkopf.2017.3544">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Rathkopf</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Antonarakis</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Shore</surname><given-names>ND</given-names></name>
<name name-style="western"><surname>Tutrone</surname><given-names>RF</given-names></name>
<name name-style="western"><surname>Alumkal</surname><given-names>JJ</given-names></name>
<name name-style="western"><surname>Ryan</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Saleh</surname><given-names>M</given-names></name>
<etal/>
</person-group>
              <article-title>Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone.</article-title>
              <source>Clin Cancer Res</source>
              <year>2017</year>
              <volume>23</volume>
              <fpage>3544</fpage>
              <lpage>51</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 46 men with castration-resistant prostate cancer and rising PSA levels treated with apalutamide [240 mg daily], 88% had at least a 50% decline in PSA levels by 12 weeks, side effects were mostly mild, and there were no treatment-related serious adverse events; no mention of ALT elevations or hepatotoxicity).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">28213364</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.smith.2018.1408">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Smith</surname><given-names>MR</given-names></name>
<name name-style="western"><surname>Saad</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Oudard</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Hadaschik</surname><given-names>BA</given-names></name>
<name name-style="western"><surname>Graff</surname><given-names>JN</given-names></name>
<name name-style="western"><surname>Olmos</surname><given-names>D</given-names></name>
<etal/>
</person-group>
              <article-title>SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer.</article-title>
              <source>N Engl J Med</source>
              <year>2018</year>
              <volume>378</volume>
              <fpage>1408</fpage>
              <lpage>18</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 1207 men with castration-resistant prostate cancer with rising levels of PSA but without detectable metastases in a randomized, placebo controlled trial, median metastasis-free survival was longer with apalutamide than placebo [40.5 vs 16.2 months], and adverse events that were more frequent with apalutamide included fatigue [30% vs 21%], rash [24% vs 6%], weight loss [16% vs 6%], falls [16% vs 9%], fractures [12% vs 7%], hypothyroidism [8% vs 2%] and seizures [0.2% vs none]; no mention of ALT elevations or hepatotoxicity).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">29420164</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.beaver.2018.2458">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Beaver</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Kluetz</surname><given-names>PG</given-names></name>
<name name-style="western"><surname>Pazdur</surname><given-names>R</given-names></name>
</person-group>
              <article-title>Metastasis-free survival &#x02013; a new end point in prostate cancer trials.</article-title>
              <source>N Engl J Med</source>
              <year>2018</year>
              <volume>378</volume>
              <fpage>2458</fpage>
              <lpage>60</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Editorial from FDA on the implications of the approval of apalutamide and application of metastasis-free survival [rather than overall survival] as an end-point in assessing efficacy of new agents for prostate cancer, stressing the importance of balancing benefit with safety and risk of adverse events).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">29949489</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.alsalama.2018.699">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Al-Salama</surname><given-names>ZT</given-names></name>
</person-group>
              <article-title>Apalutamide: first global approval.</article-title>
              <source>Drugs</source>
              <year>2018</year>
              <volume>78</volume>
              <fpage>699</fpage>
              <lpage>705</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of the structure, mechanism of action, history of development, clinical efficacy and safety of apalutamide; mentions that overall and serious adverse event rates were similar in apalutamide- and placebo-treated subjects; no mention of ALT elevations or hepatotoxicity).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">29626324</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF11">
            <element-citation publication-type="journal">
              <article-title>Apalutamide (Erleada) for prostate cancer.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2018</year>
              <volume>60</volume>
              <issue>1551</issue>
              <fpage>e124</fpage>
              <lpage>e125</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Concise review of the efficacy, safety and costs of apalutamide shortly after its approval in the US mentions side effects reported by Smith et al. [2018], but does not mention hepatotoxicity or ALT elevations).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">30036351</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.crawford.2018.956">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Crawford</surname><given-names>ED</given-names></name>
<name name-style="western"><surname>Schellhammer</surname><given-names>PF</given-names></name>
<name name-style="western"><surname>McLeod</surname><given-names>DG</given-names></name>
<name name-style="western"><surname>Moul</surname><given-names>JW</given-names></name>
<name name-style="western"><surname>Higano</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Shore</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Denis</surname><given-names>L</given-names></name>
<etal/>
</person-group>
              <article-title>Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens.</article-title>
              <source>J Urol.</source>
              <year>2018</year>
              <volume>200</volume>
              <fpage>956</fpage>
              <lpage>966</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of the development of antiandrogen therapies of prostate cancer starting with discovery of the androgen sensitive nature of prostate cancer, the effects of orchiectomy, followed by the development of androgen receptor antagonists, first generation agents flutamide and nilutamide, second generation agent bicalutamide and third generation agents enzalutamide, apalutamide and darolutamide that have more potent androgen receptor inhibition).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">29730201</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.halabi.2021.298">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Halabi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Terasawa</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Garcia-Horton</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Ayyagari</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Waldeck</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Shore</surname><given-names>N</given-names></name>
</person-group>
              <article-title>Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer.</article-title>
              <source>J Urol.</source>
              <year>2021</year>
              <volume>206</volume>
              <fpage>298</fpage>
              <lpage>307</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Comparison of outcome and adverse events in published randomized, placebo-controlled trials of darolutamide, apalutamide and enzalutamide for castration-resistant prostate cancer suggested that efficacy as assessed by improvement in metastasis-free survival was similar for all three agents, but that darolutamide therapy was associated with lower rates of adverse events, particularly fatigue, rash, falls, seizures, fractures and cognitive disorders; no mention of ALT elevations or hepatotoxicity).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">33818140</pub-id>
            </element-citation>
          </ref>
          <ref id="Apalutamide.REF.saad.2021.1541">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Saad</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Efstathiou</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Attard</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Flaig</surname><given-names>TW</given-names></name>
<name name-style="western"><surname>Franke</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Goodman</surname><given-names>OB</given-names><suffix>Jr</suffix></name>
<name name-style="western"><surname>Oudard</surname><given-names>S</given-names></name>
<etal/>
</person-group>
              <article-title>ACIS Investigators. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.</article-title>
              <source>Lancet Oncol.</source>
              <year>2021</year>
              <volume>22</volume>
              <fpage>1541</fpage>
              <lpage>1559</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 982 men with metastatic prostate cancer treated with abiraterone [1000 mg with prednisone] with or without apalutamide [240 mg], radiographic progression free survival was longer with combination therapy [22.6 vs 16.6 months], but overall survival was not different [67% vs 69%] and adverse events were more frequent with the combination, including hypertension [17% vs 10%] and ALT elevations [12% vs 4%], but there were no hepatic deaths or mention of clinically apparent liver injury).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">34600602</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Apalutamide.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Apalutamide+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Apalutamide: from PubMed.gov</ext-link>
</p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Apalutamide">Trials on Apalutamide: from ClinicalTrials.gov</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
